101 related articles for article (PubMed ID: 27793921)
1. Investigation of Bioequivalence Between Brand-name and Generic Irinotecan Products.
Saito KI; Inoue Y; Ikegami Y; Nanbo I; Onozuka M; Sano K; Yoshida H; Sakamoto T; Tatebayashi E; Fujita KI; Sasaki Y; Kitazawa T
Anticancer Res; 2016 Nov; 36(11):5957-5963. PubMed ID: 27793921
[TBL] [Abstract][Full Text] [Related]
2. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
Borgheini G
Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence and in vitro antimicrobial activity between generic and brand-name levofloxacin.
Sun HY; Liao HW; Sheng MH; Tai HM; Kuo CH; Sheng WH
Diagn Microbiol Infect Dis; 2016 Jul; 85(3):347-351. PubMed ID: 27181716
[TBL] [Abstract][Full Text] [Related]
4. [Prediction of systemic exposure of ketoprofen tapes by in vitro release test and pharmacokinetic model analysis: comparison between brand-name and generic formulations].
Awa K; Satoh H; Hori S; Sawada Y
Yakugaku Zasshi; 2012; 132(1):135-44. PubMed ID: 22214588
[TBL] [Abstract][Full Text] [Related]
5. Brand name versus generic warfarin: a systematic review of the literature.
Dentali F; Donadini MP; Clark N; Crowther MA; Garcia D; Hylek E; Witt DM; Ageno W;
Pharmacotherapy; 2011 Apr; 31(4):386-93. PubMed ID: 21449627
[TBL] [Abstract][Full Text] [Related]
6. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
[TBL] [Abstract][Full Text] [Related]
7. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
[TBL] [Abstract][Full Text] [Related]
8. [Bioequivalence and generics of index drugs with narrow therapeutic margins].
Le Corre P
Presse Med; 2010 Feb; 39(2):169-76. PubMed ID: 19932591
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.
Dong BJ; Hauck WW; Gambertoglio JG; Gee L; White JR; Bubp JL; Greenspan FS
JAMA; 1997 Apr; 277(15):1205-13. PubMed ID: 9103344
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the bioavailability and bioequivalence of generic medications.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
[TBL] [Abstract][Full Text] [Related]
11. Is bioavailability altered in generic versus brand anticonvulsants?
Jankovic SM; Ignjatovic Ristic D
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):329-32. PubMed ID: 25440299
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis for bioequivalence review.
Chow SC; Liu J
J Biopharm Stat; 1997 Mar; 7(1):97-111. PubMed ID: 9056591
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials.
Yu Y; Teerenstra S; Neef C; Burger D; Maliepaard M
Br J Clin Pharmacol; 2016 Apr; 81(4):667-78. PubMed ID: 26574160
[TBL] [Abstract][Full Text] [Related]
14. Current regulatory approaches of bioequivalence testing.
Karalis V; Macheras P
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
[TBL] [Abstract][Full Text] [Related]
15. Quantitative assessment of the switchability of generic products.
Karalis V; Bialer M; Macheras P
Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
Spence MM; Nguyen LM; Hui RL; Chan J
Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
[TBL] [Abstract][Full Text] [Related]
17. Generic selection criteria for safety and patient benefit [VIII]: Comparing the physicochemical and pharmaceutical properties of brand-name and generic diclofenac sodium tapes.
Nozawa M; Goto M; Wada Y; Yotsukura K; Gannichida A; Ishii F; Shimokawa KI
Drug Discov Ther; 2019 Jul; 13(3):150-156. PubMed ID: 31257355
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence and narrow therapeutic index drugs.
Benet LZ; Goyan JE
Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives.
Ramesh M; Ahlawat P; Srinivas NR
Biomed Chromatogr; 2010 Jan; 24(1):104-23. PubMed ID: 19852077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
